Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23334641 | 1.00 | USP2 (0.61) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL12441491 | 1.00 | USP2 (0.61) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL20670875 | 1.00 | USP2 (0.61) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL11340743 | 0.98 | USP2 (0.58) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL12441483 | 0.91 | USP2 (0.51) | USP2HTTLPAR5SPHK1 | |
| SCHEMBL18541707 | 0.91 | USP2 (0.51) | USP2HTTLPAR5SPHK1 | |
| SCHEMBL23976280 | 0.91 | ADRB2 (0.53) | USP2HTTADRB2ADRB1MEN1 | |
| Hydrochloric Acid SCHEMBL11299274 | 0.90 | USP2 (0.50) | USP2HTTLPAR5SPHK1MEN1 | |
| SCHEMBL20670848 | 0.90 | USP2 (0.61) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL3924214 | 0.90 | USP2 (0.61) | USP2HTTLPAR5SPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020101977-A1 | LIPID ETHER AMINE COMPOUNDS FOR TOPICAL TREATMENT OF CUTANEOUS DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-05-22 | — | — | WO | claimed |
| US-20210130283-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| WO-2020101977-A1 | LIPID ETHER AMINE COMPOUNDS FOR TOPICAL TREATMENT OF CUTANEOUS DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020101977-A1 | LIPID ETHER AMINE COMPOUNDS FOR TOPICAL TREATMENT OF CUTANEOUS DISEASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2017031392-A1 | LIPID COMPOUNDS FOR TREATMENT OF OBESITY, HYPERTENSION AND METABOLIC SYNDROME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2017-02-23 | — | — | WO | disclosed |
| US-8871983-B2 | Lipid compounds for suppression of tumorigenesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871983-B2 | Lipid compounds for suppression of tumorigenesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871983-B2 | Lipid compounds for suppression of tumorigenesis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2313363-A2 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | University of Florida Research Foundation, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010017550-A2 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017550-A2 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177108-A1 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS | SREBF2, SREBF1, PLIN1 | USP2 618/4885HTT 3839/4885LPAR5 202/4885 |
| US-20210130283-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | FABP7, FABP1, AIP | USP2 3169/4885HTT 4781/4885LPAR5 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.